How is the Acromegaly Market Poised for Growth: Trends and Opportunities Through 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the acromegaly market?
In recent years, the size of the acromegaly market has expanded significantly. It is projected to rise from $2.15 billion in 2024 to $2.57 billion in 2025, with a compound annual growth rate (CAGR) of 19.6%. The growth during the historic period is due to factors such as the increased prevalence of acromegaly treatments, heightened awareness about acromegaly, government-led initiatives, and the demand for effective treatments.
What will be the active cosmetics market size in the future?
In the upcoming years, rapid expansion is anticipated in the acromegaly market, with a forecasted size of $4.92 billion in 2029, growing at a compound annual growth rate (CAGR) of 17.6%. Factors contributing to this growth throughout the forecasted period include amplified investment in acromegaly treatment research and development, increased screening initiatives, amplified healthcare expenditure, and a rising demand for less invasive treatment methods. The forecast period also expects to witness specific trends, including innovations in acromegaly treatments, the evolution of targeted therapies for acromegaly, a robust drug pipeline, advancements in treatment alternatives, and progress in personalized medicine.
Get your acromegaly market report here!
https://www.thebusinessresearchcompany.com/report/acromegaly-global-market-report
What main drivers are fueling expansion in the acromegaly market?
An escalating incidence of hormonal diseases like diabetes is anticipated to fuel the acromegaly market’s growth. Endocrine disorders or hormonal diseases are health conditions emerging from the malfunctioning of the endocrine system. Diabetes stands as one of the most common and significant among these diseases. Overproduction of particular hormones, including growth hormone or cortisol, can result in acromegaly and other endocrine diseases. Furthermore, around 50% of acromegaly patients may develop insulin resistance or type 2 diabetes mellitus, given the influence of high levels of growth hormone on insulin production. For instance, the Office for Health Improvement and Disparities, a UK government department, reported in March 2024 that between March 2022 and March 2023, there was a 22% rise in the percentage of type 1 diabetic individuals receiving all eight suggested care processes, and a 21% increase for type 2 diabetes. Additionally, the percentage reaching target HbA1c levels increased to 37.9%, the maximum ever reported by the National Diabetes Audit (NDA). Consequently, the rising incidence of hormonal diseases propels the expansion of the acromegaly market.
Acromegaly Market Driver: The Effect of Genetic Abnormalities on the Growth of the Acromegaly Market
What key areas define the segmentation of the global acromegaly market?
The acromegaly market covered in this report is segmented –
1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone
2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments
5) By End Users: Hospitals, Specialty Clinics, Homecare, Other End Users
Subsegments:
1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly
2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12913&type=smp
Who are the dominant players expanding their reach in the acromegaly market?
Major companies operating in the acromegaly market are Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH., Amgen Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Ipsen Pharma S.A., Hikma Pharmaceuticals PLC, Lupin Ltd., Recordati S.p.A., Ionis Pharmaceuticals Inc., Amryt Pharma plc, Strongbridge Biopharma PLC, Aquestive Therapeutics Inc., Peptron Inc., Crinetics Pharmaceuticals, Chiasma Inc.
How are evolving market trends shaping acromegaly Strategies?
Notable businesses in the acromegaly market are concentrating their efforts on the creation of novel products and solutions, including generic lanreotide, to augment treatment choices and enhance patient results. Generic lanreotide is essentially a non-branded version of a medication utilized in the treatment of acromegaly and specific neuroendocrine tumors, functioning as a somatostatin analogue that reduces the secretion of growth hormone, thus expanding patient access to effective treatments. To illustrate, Teva Pharmaceutical Industries Ltd., a firm based in Israel with a focus on generic drugs, introduced the first and exclusive generic version of Sandostatin LAR Depot in the United States in October 2024. The drug, octreotide acetate, is designed to treat acromegaly and severe diarrhoea related to carcinoid syndrome in injectable suspension form. This new addition widens the access to vital therapy for patients in need of these treatments.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12913
Which regions are emerging as leaders in the acromegaly market?
North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Nerve Repair And Regenerative Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/nerve-repair-and-regenerative-global-market-report
Neurophysiology Devices And Equipment Global Market Report 2024
Generic Central Nervous System Drugs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
